Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | SCD | O00767 | 14/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6354166 | 0.89 | EPHX2 (0.57) | EPHX2SCDRIPK1 | |
| SCHEMBL6346657 | 0.86 | SCD (0.56) | EPHX2SCDGRIN2BHRH3 | |
| SCHEMBL5152829 | 0.79 | EPHX2 (0.63) | EPHX2RIPK1KDM5AHRH3 | |
| SCHEMBL6984405 | 0.78 | SCD (0.50) | EPHX2SCD | |
| Hydrochloric Acid SCHEMBL23928369 | 0.77 | EPHX2 (0.62) | EPHX2RIPK1KDM5AHRH3 | |
| SCHEMBL17869267 | 0.77 | EPHX2 (0.62) | EPHX2RIPK1KDM5AHRH3 | |
| SCHEMBL14413042 | 0.77 | EPHX2 (0.65) | EPHX2SCDRIPK1KDM5A | |
| SCHEMBL30729521 | 0.76 | KDM5A (0.58) | EPHX2RIPK1KDM5AHRH3NOS2 | |
| SCHEMBL6981269 | 0.76 | SCD (0.52) | EPHX2SCD | |
| SCHEMBL12791430 | 0.76 | KDM5A (0.58) | EPHX2RIPK1KDM5AHRH3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878725-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040242656-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1289950-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030078438-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2003-04-24 | — | — | US | disclosed |
| EP-1289950-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096296-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078438-A1 | Serine protease inhibitors | HPN, LPXN, PRSS1 | EPHX2 1259/4885SCD 343/4885RIPK1 1799/4885 |
| US-20040242656-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | EPHX2 1576/4885SCD 551/4885RIPK1 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.